US20010014473A1 - Method for producing cartilagetissue and implants for repairing encholndral and osteochondral defects as well as arrangement for carrying out the method - Google Patents

Method for producing cartilagetissue and implants for repairing encholndral and osteochondral defects as well as arrangement for carrying out the method Download PDF

Info

Publication number
US20010014473A1
US20010014473A1 US09/836,218 US83621801A US2001014473A1 US 20010014473 A1 US20010014473 A1 US 20010014473A1 US 83621801 A US83621801 A US 83621801A US 2001014473 A1 US2001014473 A1 US 2001014473A1
Authority
US
United States
Prior art keywords
cartilage
implant
cell space
cells
bone substitute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/836,218
Other versions
US6387693B2 (en
Inventor
Franz Rieser
Werner Muller
Pedro Bittmann
Pierre Mainil-Varlet
Christoph Saager
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zimmer GmbH
Original Assignee
Zimmer GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zimmer GmbH filed Critical Zimmer GmbH
Priority to US09/836,218 priority Critical patent/US6387693B2/en
Publication of US20010014473A1 publication Critical patent/US20010014473A1/en
Application granted granted Critical
Publication of US6387693B2 publication Critical patent/US6387693B2/en
Assigned to ZIMMER GMBH reassignment ZIMMER GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: CENTERPULSE ORTHOPEDICS LTD.
Assigned to CENTERPULSE ORTHOPEDICS LTD. reassignment CENTERPULSE ORTHOPEDICS LTD. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SULZER ORTHOPEDICS LTD.
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3612Cartilage, synovial fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/30756Cartilage endoprostheses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645Connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645Connective tissue
    • A61L27/3654Cartilage, e.g. meniscus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3817Cartilage-forming cells, e.g. pre-chondrocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843Connective tissue
    • A61L27/3852Cartilage, e.g. meniscus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655Chondrocytes; Cartilage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/56Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
    • A61B17/58Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
    • A61B17/68Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/3094Designing or manufacturing processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/30004Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006Properties of materials and coating materials
    • A61F2002/30062(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
    • A61F2002/30064Coating or prosthesis-covering structure made of biodegradable material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30316The prosthesis having different structural features at different locations within the same prosthesis; Connections between prosthetic parts; Special structural features of bone or joint prostheses not otherwise provided for
    • A61F2002/30329Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2002/30448Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements using adhesives
    • A61F2002/30449Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements using adhesives the adhesive being cement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/30756Cartilage endoprostheses
    • A61F2002/30762Means for culturing cartilage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/3094Designing or manufacturing processes
    • A61F2002/30971Laminates, i.e. layered products
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0025Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2220/005Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements using adhesives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001Designing or manufacturing processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/06Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/915Method or apparatus for preparing biological material
    • Y10S623/919Bone

Definitions

  • the invention is in the field of medicinal engineering and concerns a method according to the generic part of the first independent claim, i.e. a method for producing cartilage tissue and implants for the repair of enchondral and osteochondral defects. Furthermore, the invention concerns an arrangement for carrying out the method and implants produced according to the method.
  • Cartilage tissue substantially consists of chondrocytes and extracellular matrix.
  • the extracellular matrix mainly consists of collagen type II and proteoglycanes the components of which are exuded into the intercellular space where they are assembled to form macro molecules.
  • the chondrocytes make up about 5% of the volume of the cartilage tissue of a grown-up individual.
  • Cartilage is not vascularized and therefore its ability to regenerate is very poor, in particular in grown-up individuals and if the piece of cartilage to be regenerated exceeds but a small volume.
  • articular cartilage often shows degenerations due to wear or age or injuries due to accidents with a far larger volume than might be naturally regenerated.
  • This kind of defect of the cartilage layer makes movement and strain of the affected joint painful and can lead to further complications such as e.g. inflammation caused by synovial liquid which comes into contact with the bone tissue due to the defect in the cartilage layer covering the bone.
  • chondrocytes taken from the patient are multiplied in a mono-layer culture and, for further reproduction, are then introduced into a three-dimensional collagen matrix in form of a gel or a sponge in which matrix they settle and become immobile.
  • the defect cartilage location is filled with the material consisting of the collagen matrix and the cells.
  • a piece of periosteum is sutured over it. The cartilage regeneration in the region of this kind of transplant is considerably better than without the transplant.
  • chondrocytes or cells able to take over a chondrocyte function are introduced into a biocompatible, resorbable matrix (32 ⁇ 10 6 to 120 ⁇ 10 6 cells per cm 3 ) in which matrix the cells are immobilized.
  • This matrix is implanted, whereby a cartilage-like tissue forms in vivo.
  • the chondrocytes used for the implant are previously cultivated, first in a mono-layer culture and then suspended, whereby they assemble to form aggregates of 30 to 60 cells.
  • chondrocytes are applied to a layer of filter material (MILLICELL®-CM having a pore size of 0.4 ⁇ m) in a mono-layer with a cell density of 1.5 ⁇ 10 6 cells per cm 2 .
  • MILLICELL®-CM having a pore size of 0.4 ⁇ m
  • cartilage can be cultivated in so called high density cell cultures.
  • Cells are applied to a carrier and are cultured in a higher density than used for mono-layer culturing.
  • the culture medium is added only one to two hours after bringing the cells onto the carrier.
  • the cell layer on the carrier contracts and so-called microspheres with diameters in the range of 1 mm form.
  • a cartilage-like tissue forms inside these microspheres while fibrous cartilage (perichondrium) forms on their surface.
  • fibrous cartilage peripheralchondrium
  • Sittinger et al. (Biomaterials Vol. 17, No. 10, May 1996, Guilford GB) suggest to introduce vital cells into a three-dimensional matrix for growing cartilage in vitro and to then enclose the loaded matrix into a semi-permeable membrane. During the cartilage growth, this membrane is to prevent the culture medium to wash away compounds produced by the cells and being used for constructing the extracellular matrix. Implantation of cell cultures enclosed in this kind of membranes is also known for preventing immune reactions.
  • the problem of de-differentiation of chondrocytes is solved by immobilizing the chondrocytes in correspondingly dense cultures in a monolayer or in a three-dimensional matrix. It shows that in this manner chondrocytes reproduce themselves without substantial de-differentiation and form an extracellular matrix which is at least similar to the extracellular matrix of natural cartilage.
  • the three-dimensional matrix is mostly not only used for immobilizing the cells but also for mechanical stability after implantation which is needed because none of the cartilage tissues produced in the named manner has a stability which could withstand even a greatly reduced strain.
  • the object of the invention is to create a device with which suitable cartilage tissue or implants which at least partly consist of such cartilage tissue can be produced in vitro, the cartilage or implant serving for implantation, especially implantation in articular cartilage defects.
  • the cartilage or implant serving for implantation, especially implantation in articular cartilage defects.
  • an in vitro environment in particular a three-dimensional such environment, in which environment chondrocytes or other cells capable of a chondrocyte function do not de-differentiate over a longer culture period and perform their function actively or in which environment cells differentiate to become active chondrocytes respectively.
  • the main part of the object is achieved as not de-differentiating, vital chondrocytes according to their natural function produce the extracellular matrix characteristic for cartilage and together with this form the cartilage tissue to be created.
  • the implants produced according to the invention consist at least partly of cartilage tissue produced in vitro and are especially suited for the repair of enchondral or osteochondral joint defects. They are to be producible for any possible depth of such a defect and a defect repaired with the inventive implant is to be able to carry a normal load as soon as possible after implantation, i.e. a load created either by pressing or by shearing forces.
  • the inventive method is based on the finding that chondrocytes can build satisfactory cartilage tissue if it is made possible that a sufficiently high concentration of compounds produced by the cells and segregated into extracellular spaces is achieved in a short initial phase and is maintained during the whole culture period. Under these conditions the differentiated function of the chondrocytes is fully maintained (they do not de-differentiate into fibroblasts) and/or it is possible to differentiate corresponding cells, especially mesenchymal stem cells or other mesenchymal cells or even fibroblasts to a corresponding function.
  • the first condition is fulfilled by creating a cell community in which there is, at least at the beginning of the culture period, a density of cells such that the cells are capable to produce the amount of compounds necessary for the mentioned concentrations in the spaces between the cells.
  • the second condition is fulfilled by accommodating the cell community in a restricted cell space in which washing out of the named compounds from the extracellular spaces is prevented.
  • the named compounds are especially autocrine factors and substances serving as components for building the extracellular structure. These components are especially aggrecanes, link-proteins and hyalorunates for building proteoglycane-aggregates and preliminary stages of collagens to eventually form collagen-fibrils of type II.
  • the cells are not immobilized for the in vitro culture but have space at their disposition, space without a three-dimensional, artificial matrix in which space the two conditions mentioned above are fulfilled, in which space it is however largely left to the cells how they are to settle relative to each other. It shows that in this kind of free cell space, cells fully practice their chondrocyte-function and a cartilage tissue having sufficient stability for implantation and being able to carry at least part of the normal load after implantation can be cultured.
  • cells which are capable of a chondrocyte-function are introduced into an empty cell space, i.e. into a space containing culture medium only, such that there is a cell density of ca. 5 ⁇ 10 7 to 10 9 cells per cm 3 in the cell space. This density amounts to a space occupation of ca. 5% to 100% at an approximate cell volume of 10 3 ⁇ m 3 .
  • the cell space has at least partly permeable walls and is introduced into a space filled with culture medium for the length of the culture period which medium is periodically renewed in known manner.
  • the cell space is arranged to be stationary in the culture medium or it is moved in it (relative movement between cell space and culture medium surrounding the cell space).
  • the permeability of the permeable parts of the cell space wall and the relative movement are to be matched to the relative dimension of the cell space (depending on the cartilage to be produced) such that the condition of the washing-out-prevention is fulfilled.
  • semi-permeable wall regions with a permeability of 10.000 to 100.000 Dalton (10 to 100 kDa) are suitable, especially for agitated cultures and for cell spaces of large dimensions (three-dimensional forms).
  • the named autocrine factors and components for building the macromolecules of the extracellular cartilage matrix have molecular weights which are such that they cannot pass through a membrane with the named permeability.
  • the cell space has substantially three functions:
  • the cell space keeps the community of the (not immobilize) cells together at a sufficient density such that they do not loose their specific functionality
  • the cell space restricts the growth of cartilage such that by choice of the form of the cell space the form of the cartilage being formed is controlled;
  • the cell space wall allows the supply of the cells with culture medium but prevents the washing out of the substances produced by the cells and necessary for the growth of cartilage.
  • a part of the permeable wall of the cell space can additionally have the function of an implant part as will be described in more detail further below.
  • the cells to be brought into the cell space are chondrocytes, mesenchymal stem cells or other mesenchymal cells. These cell types are isolated in known manner from cartilage tissue, from bone or bone marrow or from connective tissue or fatty tissue. Fibroblasts are also suited, e.g. if factors are added to the culture medium or the cell space which factors effect differentiation of the fibroblasts to chondrocytes or if the cells are treated with this kind of factor before they are brought into the cell space. The cells can also be multiplied in vitro before being brought into the cell space.
  • cartilage tissue being formed can, as soon as it has a sufficient mechanical strength, be removed from the cell space and e.g. be further cultivated floating freely in the culture medium or it can remain in the cell space up to directly before being used.
  • Cartilage tissue produced according to the inventive method is used as implant as implant part or when containing autologous cells as cell-autotransplant or it can be used for scientific in vitro purposes.
  • FIG. 1 The following Figures illustrate the inventive method, the arrangement for carrying out the inventive method as well as examples of implants produced by means of the inventive method.
  • the shown examples are implants for repair of enchondral and osteochondral defects in joints.
  • using the inventive method it is also possible to produce other implants such as e.g. auditory bones or cartilage for plastic surgery e.g. nose cartilage, orbital floors, ear conchs or parts thereof.
  • FIGS. 1 to 4 show four exemplified arrangements (in section) for carrying out the inventive method for in vitro production of cartilage tissue
  • FIGS. 5 to 7 show chondroitin and collagen contents of different experimental cartilage cultures (of cultures according to the inventive method and of reference cultures according to known methods) in comparison with natural articular cartilage;
  • FIGS. 8 and 9 for illustrating the mechanical properties of cartilage produced according to the inventive method, show forces straining such cartilage (FIG. 8) and straining native cartilage (FIG. 9);
  • FIGS. 10 to 13 show light-microscopical and electron-microscopical micrographs of cartilage produced according to the inventive method and of native cartilage.
  • FIG. 14 shows a section through an implant produced according to the inventive method as illustrated in FIG. 2 or 3 , the implant comprising a carrier layer and a cartilage layer (boundary region between the two layers in section perpendicular to the layers);
  • FIGS. 15 and 16 show exemplified embodiments of the inventive implants according to FIG. 14 in section perpendicular to the cartilage layer;
  • FIGS. 17 to 20 show examples of applications of implants produced according to the inventive method for the repair of enchondral and osteochondral joint defects (sections perpendicular to the cartilage layer).
  • FIG. 1 shows in section an exemplified arrangement for the inventive in vitro production of cartilage tissue.
  • This arrangement substantially consists of a defined cell space 1 into which the cells are introduced and which is arranged in a culture medium space 2 .
  • At least part of the boundary between the cell space 1 and the culture medium space 2 is formed by a permeable wall, e.g. a semi-permeable membrane 3 .
  • the remaining parts of the boundary separating the cell space 1 from the culture medium space 2 are not permeable and consist e.g. of plastic components which give the cell space 1 the predetermined form and hold the semi-permeable membrane in place.
  • an inner ring 4 and two outer snap-rings 5 and 6 together with two e.g. substantially circular pieces of semi-permeable membrane enclose a cell space 1 in the form of a circular disc.
  • the semi-permeable membrane 3 has a permeability of 10.000 to 100.000 Dalton. It e.g. consists of the same material as a corresponding dialyse tube. It is obvious that in the same manner as shown in FIG. 1, cell spaces of the most various forms can be created, into which spaces cells are introduced and in which spaces these cells build cartilage tissue, the cartilage tissue substantially assuming the form of the cell space 1 or the form of the one part of cell space 1 which during the culture period faces downward in the direction of gravity.
  • the culture medium space 2 is a freely selectable space in which the culture medium is periodically exchanged in known manner. If the cell space 1 is to be moved in the culture medium space 2 the culture medium space is e.g. a spinner bottle.
  • the inventive method is e.g. carried out as follows:
  • Cells, tissue particles or mixtures of cells and/or tissue particles as described further above are suspended e.g. in culture medium and are introduced into the free cell space such that the cell density is in the range between 5 ⁇ 10 7 and 10 9 cells per cm 3 .
  • the cell space is closed and introduced into the culture medium space and is left there for a period of time in the range of approximately three weeks.
  • the cartilage tissue formed in the cell space is removed from the cell space and is either cultivated further swimming freely on a culture medium or is directly used as implant or as transplant or for scientific investigations respectively.
  • implants consisting of cartilage tissue, e.g. auditory bones, nose cartilage, orbital floors or parts thereof are produced.
  • FIG. 2 shows a further embodiment of a cell space for carrying out the inventive method.
  • the cell space 1 is flat and its one side is limited by an open pore, rigid or plastically deformable plate 7 made of a possibly biologically degradable bone substitute material, the other side by a permeable wall, e.g. a semi-permeable membrane 3 or a more coarsely porous wall.
  • the cell space has a height of e.g. ca. 3 to 5 mm and any flat form and extension.
  • a cell space as shown in FIG. 2 is especially suited for the production of an implant for repair of a osteochondral defect.
  • the implant comprises not only the cartilage tissue grown in the flat cell space but also the bone substitute plate 7 .
  • This bone substitute plate 7 thus has substantially two functions: during the growth of the cartilage, it serves as permeable wall for the cell space 1 and in the finished implant, it serves as anchoring substrate for the cartilage layer, whereby after implantation this bone substitute material is colonized in known manner by cells immigrating from the adjacent vital bone tissue.
  • the cell space 1 is e.g., as shown in FIG. 2, arranged to be stationary with the bone substitute plate 7 facing downward such that the cells settle on the bone substitute plate 7 due to the effect of gravity.
  • the bone substitute plate 7 must be formed such that the cartilage tissue growing in the cell space 1 is able to grow together with the bone substitute plate 7 in an intermediate region, thus forming a two part implant which can resist shearing forces.
  • This kind of growing together is achieved by choosing the porosity of at least the one surface of the bone substitute plate on which the cartilage is cultivated such that the collagen fibrils built in the extracellular cartilage matrix can grow into the pores and can such anchor the new cartilage in the bone substitute plate. It shows that for this kind of anchoring of the collagen fibers, pores of ca. 1 to 20 ⁇ m are suitable.
  • the bone substitute plate 7 is to fulfill the following conditions:
  • bone substitute material known osteo-inductive and/or osteo-conductive materials are suitable, advantageously biologically degradable such materials which have the mentioned open porosity and which can be processed to rigid or plastically deformable plates.
  • Plastically deformable plates can e.g. be produced from collagen I, from collagen II and hydroxyapatite or from polylactic acid.
  • Rigid plates can be formed from tricalcium-phosphate, from hydroxyapatite or from other inorganic bone substitute materials.
  • cartilage tissue is grown in vitro but also an implant is produced which comprises a pre-formed, grown together cartilage/bone-intermediate region.
  • FIG. 3 shows a further, exemplified arrangement for carrying out the inventive method.
  • the bone substitute plate 7 is not arranged as part of the permeable wall of the cell space 1 but lies within the cell space which cell space is e.g. limited by semi-permeable membranes 3 . It is obvious that in this kind of arrangement the bone substitute plate 7 does not have to take over the function of a convection barrier and that due to this the porosity and thickness of the plate can be chosen at greater liberty.
  • FIG. 3 The arrangement shown in FIG. 3 is especially suitable for thin, plastically deformable bone substitute plates 7 which are complicated to handle as cell space walls.
  • FIG. 4 shows schematically a further embodiment of a cell space 1 which space is especially suitable for cultivating very thin cartilage layers which are grown together with a bone substitute plate.
  • the cell space in FIG. 4 is open towards the top such that at least in the first one to two weeks cultivation must take place under stationary culture conditions.
  • a bone substitute plate 7 is provided as carrier for the cells and the cells are not applied to the carrier as mono-layer and are not immobilized with the help of an attachment factor.
  • FIGS. 5 to 7 show results from experiments with the inventive method (experimental arrangement substantially as outlined in FIG. 1). Dialyse tubes were used as semi-permeable membranes.
  • Chondrocytes were isolated from bovine shoulders using known isolation methods. The cells were introduced into the dialyse tubes and these were moved in a spinner bottle during the culture period, whereby the cells settled on the bottommost end of the tubes. HAM-F12 with 5 to 15% serum was used as culture medium. The culture medium was changed every two days.
  • FIG. 5 shows the contents of chondroitin sulfate and collagen of the cartilage tissue produced according to the inventive method (in ⁇ g per ml of cartilage tissue) as a function of the duration of the culture period (20, 29 and 49 days) in comparison with corresponding values of cartilage from bovine shoulders (age: eighteen months).
  • the results show that the content of chondroitin sulfate can be even higher in the cartilage produced in vitro than in natural cartilage, that the content of collagen however is considerably lower.
  • FIGS. 6 and 7 also show, as a function of the duration of the culture period (0, 7, 20 and 40 days), chondroitin sulfate (FIG. 6) and collagen contents (FIG. 7) in reference cultures A and B and of cartilage tissue grown according to the inventive method after 40 days of culture time (C: cartilage growing in the cell space in the region of the settled cells, D: culture medium in the cell space above the settled cells).
  • C cartilage growing in the cell space in the region of the settled cells
  • D culture medium in the cell space above the settled cells.
  • chondrocytes were embedded in alginate spheres and cultivated in a stationary culture (reference A) and in a spinner bottle (reference B).
  • FIGS. 6 and 7 make it clear that the cartilage structure in the experimental arrangement according to the invention is considerably more successful than in the reference experiments.
  • FIGS. 8 and 9 show results of stress experiments on cartilage produced according to the invention (FIG. 8) and on native cartilage (FIG. 9) in order to illustrate the mechanical properties of the cartilage produced according to the inventive method (for culture conditions see above) compared with the mechanical properties of native bovine cartilage.
  • the experiment consists in pressing a punch into the cartilage with a constant speed (1 micrometer per second) and to stop the punch at a penetration depth of 200 ⁇ m while registering the punch force. This force first rises approximately proportionally to the penetration depth and after stopping the punch decreases (visco-elastic force reduction due to loss of liquid of the cartilage tissue).
  • FIGS. 8 and 9 show the punch force in Newton (N) as a function of the time in seconds (s).
  • N the punch force in Newton
  • s the time in seconds
  • the stress experiment with the cartilage produced according to the invention (FIG. 8) was carried out with a punch having a diameter of 20 mm and shows a maximal pressure of ca. 0.8N/cm 2 .
  • the experiment with the native cartilage was carried out with a punch having a diameter of 5 mm and shows a maximal pressure of ca. 30N/cm 2 .
  • FIGS. 10 to 13 show light-microscopical micrographs (FIGS. 10 and 11) and electron-microscopical micrographs (FIGS. 12 and 13) of cartilage produced according to the inventive method (FIGS. 10 and 11) and of human cartilage from the medium zone (FIGS. 12 and 13).
  • FIGS. 10 and 11 clearly show that the cartilage produced according to the inventive method contains considerably more chondrocytes than the native cartilage which can be interpreted as growth stage for the cartilage cultivated in vitro.
  • FIGS. 12 and 13 in which organelles are easily visible in the chondrocytes (marked with arrows).
  • the organelles are narrow suggesting little synthesis activity; in the cartilage produced according to the invention they are distinctly enlarged which suggests an intense synthesis activity, i.e. a growth stage.
  • cartilage tissue produced according to the invention must be looked at as a kind of embryonic cartilage tissue which, however has the ability to develop in vivo (after implantation) into ‘grown-up’ cartilage.
  • FIG. 14 schematically shows a histological section (magnification ca. 100-fold) through the intermediate region between cartilage tissue and bone substitute plate of an implant which was produced in an arrangement according to one of the FIGS. 2 to 4 .
  • the cartilage tissue 10 and the bone substitute plate 7 are connected to each other in an intermediate region in the manner of positive engaging means due to the cartilage tissue having grown into uneven surface places of the bone substitute plate 7 .
  • FIGS. 15 and 16 show exemplified embodiments of implants which are produced according to methods as described in connection with FIGS. 2 to 4 (section through cartilage layer 10 ).
  • the implants comprise an intermediate region in which the cartilage tissue is grown together with the bone substitute plate 7 , as shown in FIG. 14.
  • the bone substitute plate 7 with the cartilage layer 10 having grown on it is separated from the other wall components of the cell space.
  • the implant consisting of the cartilage layer 10 and the bone substitute plate 7 is reduced to the demanded size and form, if required, and/or is fixed to a further piece 12 of bone substitute material.
  • a further piece 12 of a similar or different bone substitute material is attached on the one side of the bone substitute plate 7 opposite to the cartilage layer 10 , using a known advantageously biologically degradable cement.
  • FIGS. 17 to 20 show enchondral and osteochondral defects which are repaired with exemplified embodiments of inventive implants.
  • FIG. 17 shows an enchondral defect with a defined form made by drilling or milling, i.e. a defect which lies in the native cartilage layer 20 and does not affect the bone tissue 21 underneath the cartilage layer 20 .
  • This kind of defect has, in the human case, a depth of maximally ca. 3 mm and can affect any extent of the cartilage surface.
  • a piece of cartilage tissue 10 ′ is inserted into the prepared defect which cartilage tissue was e.g. cultivated in an arrangement according to FIG. 1 and which cartilage tissue after cultivation was made to fit the form of the defect by cutting or punching, if required.
  • the implant is fixed with known means: e.g. with a piece of periosteum which is sutured or glued over the implant, with a glue being introduced between native cartilage and implant (e.g. fibrin glue) or by suturing the implant to the surrounding native cartilage.
  • a glue being introduced between native cartilage and implant (e.g. fibrin glue) or by suturing the implant to the surrounding native cartilage.
  • FIG. 18 shows a small osteochondral defect which has been prepared for implantation by drilling an opening having a defined form (surface extension up to ca. 10 mm, depth up to ca. 3 mm in the bone tissue), i.e. a defect which does not only affect the native cartilage tissue 20 but also the bone tissue 21 beneath it.
  • This defect is repaired with an implant according to FIG. 15, which implant is fixed with one or several pins. Two pins are shown. The one pin 22 . 1 is driven through the implant from its surface by the surgeon, the other pin 22 . 2 is previously arranged in the bone substitute plate 7 of the implant and is driven into the bone by pressing on the surface of the implant.
  • FIG. 19 shows a prepared osteochondral defect having a depth of 20 to 30 mm and repaired by implantation of an inventive implant according to FIG. 16. Shearing forces are again taken up by the region where the cartilage layer 10 and the bone substitute plate 7 are grown together. As the cement-connection 13 is positioned within the native bone 21 it is not strained by shearing and thus need not be reinforced by means of a pin.
  • the repair shown in FIG. 18 can also be carried out by filling the lower part of the bore with bone substitute material and by implanting an implant according to FIG. 15, possibly by means of a cement layer 13 .
  • a plurality of implants according to FIG. 19 can be provided (mosaic plasty).
  • FIG. 20 shows a large and deep osteochondral defect. It is so large that the cartilage area to be repaired can no longer be approximated with an even area. This kind of defect can, as indicated further above, be repaired with mosaic plasty.
  • the inventive implants are not limited regarding surface size and as the bone substitute plates 7 can be made of a plastically deformable material, the defect is more easily repaired according to FIG. 20 with an implant according to FIG. 15. For this purpose, the defect is cut out to a depth of a few millimeters into bone 21 and to a defined form, deeper regions are filled with a plastic bone substitute material and the implant is positioned in the defect and fixed with suitable means.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cartilage tissue and implants comprising tissue are produced in vitro starting from cells having the ability to form an extracellular cartilage matrix. Such cells are brought into a cell space (1) and are left in this cell space for producing an extracellular cartilage matrix. The cells are brought into the cell space to have a cell density of ca. 5×107 to 109 cells per cm3 of cell space. The cell space (1) is at least partly separated from a culture medium space (2) surrounding the cell space by means of a semi-permeable wall (3) or by an open-pore wall acting as convection barrier. The open-pore wall can be designed as a plate (7) made of a bone substitute material and constituting the bottom of the cell space (1). The cells settle on such a plate (7) and the cartilage tissue growing in the cell space (1). The cells settle on such a plate (7) and the cartilage tissue growing in the cell space (1) grows into pores or surface roughness of the plate, whereby an implant forms which consists of a bone substitute plate (7) and a cartilage layer covering the plate and whereby the two implant parts are connected to each other in positively engaged manner by being grown together.

Description

  • The invention is in the field of medicinal engineering and concerns a method according to the generic part of the first independent claim, i.e. a method for producing cartilage tissue and implants for the repair of enchondral and osteochondral defects. Furthermore, the invention concerns an arrangement for carrying out the method and implants produced according to the method. [0001]
  • Cartilage tissue substantially consists of chondrocytes and extracellular matrix. The extracellular matrix mainly consists of collagen type II and proteoglycanes the components of which are exuded into the intercellular space where they are assembled to form macro molecules. The chondrocytes make up about 5% of the volume of the cartilage tissue of a grown-up individual. [0002]
  • Articular cartilage coating the ends of flexibly joined bones takes over the function of the load distribution in the loaded joint. For this function the cartilage tissue is capable to take up water and to release it again under pressure. Furthermore, the cartilage surfaces serve as sliding surfaces in the joints. [0003]
  • Cartilage is not vascularized and therefore its ability to regenerate is very poor, in particular in grown-up individuals and if the piece of cartilage to be regenerated exceeds but a small volume. However, articular cartilage often shows degenerations due to wear or age or injuries due to accidents with a far larger volume than might be naturally regenerated. This kind of defect of the cartilage layer makes movement and strain of the affected joint painful and can lead to further complications such as e.g. inflammation caused by synovial liquid which comes into contact with the bone tissue due to the defect in the cartilage layer covering the bone. [0004]
  • For these reasons efforts have been made for quite some time to replace or repair missing or damaged cartilage, especially articular cartilage by corresponding surgery. [0005]
  • It is known to repair defects concerning articular cartilage or articular cartilage and the bone tissue beneath it by milling the defect location to form a bore of an as precise geometry as possible, by extracting a column of cartilage and bone of the same geometry from a less strained location of e.g. the same joint by means of boring or punching and by inserting this column into the bore. In the same manner, larger defects with several bores are repaired (mosaic plasty). These methods are successful but the actual problem is substantially shifted from a strained part of a joint to a less strained part of the joint and therefore, is not really solved. [0006]
  • It is also suggested, e.g. in the publication U.S. Pat. No. 3,703,575 (Thiele), to repair defects of cartilage with purely artificial implants (e.g. gels containing proteins and polysaccharides). It shows, however, that only restricted success can such be achieved and therefore in recent development solutions to the problem have been thought in various directions, in particular based on vital autologous or homologue cells. Vital chondrocytes or cells able to take over a chondrocyte function are e.g. cultivated in vitro and then implanted; or vital chondrocytes are introduced in artificial implants; or vital cartilage tissue is cultivated at least partly in vitro and is then implanted. This means that in these recent developments the aim is to produce vital cartilage in vitro and to implant such cartilage or to populate a defect site with cartilage forming cells which cells are then to build tissue at least similar to cartilage. [0007]
  • Examples of such methods are described in the following publications: [0008]
  • According to the method described in U.S. Pat. No. 4,846,835 (Grande), chondrocytes taken from the patient are multiplied in a mono-layer culture and, for further reproduction, are then introduced into a three-dimensional collagen matrix in form of a gel or a sponge in which matrix they settle and become immobile. After ca. three weeks of cell reproduction, the defect cartilage location is filled with the material consisting of the collagen matrix and the cells. In order to hold the implant in the defect location, a piece of periosteum is sutured over it. The cartilage regeneration in the region of this kind of transplant is considerably better than without the transplant. [0009]
  • According to the method described in U.S. Pat. No. 5,053,050 (Itay), chondrocytes or cells able to take over a chondrocyte function are introduced into a biocompatible, resorbable matrix (32×10[0010] 6 to 120×106 cells per cm3) in which matrix the cells are immobilized. This matrix is implanted, whereby a cartilage-like tissue forms in vivo. The chondrocytes used for the implant are previously cultivated, first in a mono-layer culture and then suspended, whereby they assemble to form aggregates of 30 to 60 cells.
  • According to the method described in U.S. Pat. No. 4,963,489 (Naughton), again a three-dimensional, artificial matrix is used as carrier material for the implant. This matrix is used for the cell culture preceding the implantation and is covered with a layer of connective tissue for better adhesion and better supply of the cells to be cultivated. After in vitro cell reproduction on the three-dimensional matrix, the matrix is implanted. The implanted cells form the cartilage tissue in vivo. [0011]
  • According to the method described in PCT-WO90/12603 (Vacanti et al.), again a three-dimensional matrix is used which matrix consists of degradable polymer fiber materials and on which matrix the cells settle. The cells cultivated on the matrix or in mono-layer cell cultures and then introduced into the matrix are implanted adhering to the matrix and therefore, in an immobilized state. The matrix is degraded in vivo and is gradually replaced by extracellular matrix built by the cells. [0012]
  • According to the method described in U.S. Pat. No. 5,326,357 (Kandel), chondrocytes are applied to a layer of filter material (MILLICELL®-CM having a pore size of 0.4 μm) in a mono-layer with a cell density of 1.5×10[0013] 6 cells per cm2. In vitro culturing of the monolayer produces a thin cartilage layer in two to four weeks which, in its structure obviously corresponds to the natural articular cartilage and can be implanted as such.
  • It is also known that cartilage can be cultivated in so called high density cell cultures. Cells are applied to a carrier and are cultured in a higher density than used for mono-layer culturing. The culture medium is added only one to two hours after bringing the cells onto the carrier. After one to three culture days, the cell layer on the carrier contracts and so-called microspheres with diameters in the range of 1 mm form. On further culturing, a cartilage-like tissue forms inside these microspheres while fibrous cartilage (perichondrium) forms on their surface. For implants, this kind of inhomogeneous tissue is not suitable. [0014]
  • Sittinger et al. (Biomaterials Vol. 17, No. 10, May 1996, Guilford GB) suggest to introduce vital cells into a three-dimensional matrix for growing cartilage in vitro and to then enclose the loaded matrix into a semi-permeable membrane. During the cartilage growth, this membrane is to prevent the culture medium to wash away compounds produced by the cells and being used for constructing the extracellular matrix. Implantation of cell cultures enclosed in this kind of membranes is also known for preventing immune reactions. [0015]
  • All methods named above attempt to produce cartilage at least partly in vitro, i.e. to produce cartilage using vital natural cells under artificial conditions. The problem encountered in these attempts is the fact that chondrocytes in these in vitro conditions have the tendency to de-differentiate into fibroblasts relatively rapidly, or the fact that it is possible to differentiate fibroblasts to a chondrocyte function under very specific culture conditions only. By the de-differentiation the chondrocytes among other things loose the ability to produce type II collagen which is one of the most important compounds of cartilage tissue. [0016]
  • According to the methods mentioned above, the problem of de-differentiation of chondrocytes is solved by immobilizing the chondrocytes in correspondingly dense cultures in a monolayer or in a three-dimensional matrix. It shows that in this manner chondrocytes reproduce themselves without substantial de-differentiation and form an extracellular matrix which is at least similar to the extracellular matrix of natural cartilage. The three-dimensional matrix is mostly not only used for immobilizing the cells but also for mechanical stability after implantation which is needed because none of the cartilage tissues produced in the named manner has a stability which could withstand even a greatly reduced strain. [0017]
  • The object of the invention is to create a device with which suitable cartilage tissue or implants which at least partly consist of such cartilage tissue can be produced in vitro, the cartilage or implant serving for implantation, especially implantation in articular cartilage defects. For achieving this object it is necessary to create an in vitro environment, in particular a three-dimensional such environment, in which environment chondrocytes or other cells capable of a chondrocyte function do not de-differentiate over a longer culture period and perform their function actively or in which environment cells differentiate to become active chondrocytes respectively. By solving the problem of this environment, the main part of the object is achieved as not de-differentiating, vital chondrocytes according to their natural function produce the extracellular matrix characteristic for cartilage and together with this form the cartilage tissue to be created. [0018]
  • The implants produced according to the invention consist at least partly of cartilage tissue produced in vitro and are especially suited for the repair of enchondral or osteochondral joint defects. They are to be producible for any possible depth of such a defect and a defect repaired with the inventive implant is to be able to carry a normal load as soon as possible after implantation, i.e. a load created either by pressing or by shearing forces. [0019]
  • This object is achieved by the method as defined in the claims. [0020]
  • The inventive method is based on the finding that chondrocytes can build satisfactory cartilage tissue if it is made possible that a sufficiently high concentration of compounds produced by the cells and segregated into extracellular spaces is achieved in a short initial phase and is maintained during the whole culture period. Under these conditions the differentiated function of the chondrocytes is fully maintained (they do not de-differentiate into fibroblasts) and/or it is possible to differentiate corresponding cells, especially mesenchymal stem cells or other mesenchymal cells or even fibroblasts to a corresponding function. [0021]
  • The first condition is fulfilled by creating a cell community in which there is, at least at the beginning of the culture period, a density of cells such that the cells are capable to produce the amount of compounds necessary for the mentioned concentrations in the spaces between the cells. The second condition is fulfilled by accommodating the cell community in a restricted cell space in which washing out of the named compounds from the extracellular spaces is prevented. [0022]
  • The named compounds are especially autocrine factors and substances serving as components for building the extracellular structure. These components are especially aggrecanes, link-proteins and hyalorunates for building proteoglycane-aggregates and preliminary stages of collagens to eventually form collagen-fibrils of type II. [0023]
  • According to the inventive method, the cells are not immobilized for the in vitro culture but have space at their disposition, space without a three-dimensional, artificial matrix in which space the two conditions mentioned above are fulfilled, in which space it is however largely left to the cells how they are to settle relative to each other. It shows that in this kind of free cell space, cells fully practice their chondrocyte-function and a cartilage tissue having sufficient stability for implantation and being able to carry at least part of the normal load after implantation can be cultured. [0024]
  • According to the inventive method, cells which are capable of a chondrocyte-function are introduced into an empty cell space, i.e. into a space containing culture medium only, such that there is a cell density of ca. 5×10[0025] 7 to 109 cells per cm3 in the cell space. This density amounts to a space occupation of ca. 5% to 100% at an approximate cell volume of 103 μm3.
  • The cell space has at least partly permeable walls and is introduced into a space filled with culture medium for the length of the culture period which medium is periodically renewed in known manner. During the culture period, the cell space is arranged to be stationary in the culture medium or it is moved in it (relative movement between cell space and culture medium surrounding the cell space). [0026]
  • The permeability of the permeable parts of the cell space wall and the relative movement are to be matched to the relative dimension of the cell space (depending on the cartilage to be produced) such that the condition of the washing-out-prevention is fulfilled. [0027]
  • For all cases, semi-permeable wall regions (semi-permeable membranes) with a permeability of 10.000 to 100.000 Dalton (10 to 100 kDa) are suitable, especially for agitated cultures and for cell spaces of large dimensions (three-dimensional forms). The named autocrine factors and components for building the macromolecules of the extracellular cartilage matrix have molecular weights which are such that they cannot pass through a membrane with the named permeability. [0028]
  • It shows that for stationary cultures and cell spaces with at least one small dimension (thin layers) open-pore walls with considerably larger pores (up to the region of 10 to 20 μm) which cannot be effective as semi-permeable walls but merely as convection barriers are sufficient and that possibly the cell space can even be open on one side. [0029]
  • Especially in cell spaces not being moved and containing cells at a density in the lower region of the given density range, the cells settle in the direction of gravity and form cartilage tissues in the form of layers. For producing more three-dimensional cartilage forms, agitated cell spaces prove to be advantageous. [0030]
  • For specific cultures and especially for specific forms and sizes of cell spaces the optimal arrangement (with or without movement of the cell space in the culture medium) and the optimal condition of the wall of the cell space or the permeable parts of this wall respectively must be determined by experiment. [0031]
  • The cell space has substantially three functions: [0032]
  • The cell space keeps the community of the (not immobilize) cells together at a sufficient density such that they do not loose their specific functionality; [0033]
  • the cell space restricts the growth of cartilage such that by choice of the form of the cell space the form of the cartilage being formed is controlled; [0034]
  • the cell space wall allows the supply of the cells with culture medium but prevents the washing out of the substances produced by the cells and necessary for the growth of cartilage. [0035]
  • For producing implants which only partly consist of cartilage tissue, a part of the permeable wall of the cell space can additionally have the function of an implant part as will be described in more detail further below. [0036]
  • The cells to be brought into the cell space are chondrocytes, mesenchymal stem cells or other mesenchymal cells. These cell types are isolated in known manner from cartilage tissue, from bone or bone marrow or from connective tissue or fatty tissue. Fibroblasts are also suited, e.g. if factors are added to the culture medium or the cell space which factors effect differentiation of the fibroblasts to chondrocytes or if the cells are treated with this kind of factor before they are brought into the cell space. The cells can also be multiplied in vitro before being brought into the cell space. [0037]
  • It is not necessary to isolate specific cell types from donor tissue, i.e. mixtures of different cells as usually contained in such tissues can be brought into the cell space as such. It also shows that a complete separation of the cells from the intracellular matrix of the donor tissue is not necessary and thus possibly tissue particles or mixtures of isolated cells and tissue particles can be brought into the cell space instead of cells only. However, care has to be taken that the necessary cell density is achieved in the cell space possibly by partly separating the cells from their extracellular matrix, e.g. by means of a short enzymatic digestion. [0038]
  • It shows that with the known culture media such as e.g. HAM-F12 to which 5 to 15% serum is advantageously added, good results can be achieved. Furthermore, known growth factors and other components of culture media which support the reproduction of the cells and the forming of the cartilage matrix can be added to the culture medium. [0039]
  • It shows that in the culture conditions created according to the inventive method the chondrocytes remain active and do not de-differentiate such that the space is filled with cartilage tissue in a culture period in the range of ca. three weeks. The cartilage tissue being formed can, as soon as it has a sufficient mechanical strength, be removed from the cell space and e.g. be further cultivated floating freely in the culture medium or it can remain in the cell space up to directly before being used. [0040]
  • Cartilage tissue produced according to the inventive method is used as implant as implant part or when containing autologous cells as cell-autotransplant or it can be used for scientific in vitro purposes. [0041]
  • The following Figures illustrate the inventive method, the arrangement for carrying out the inventive method as well as examples of implants produced by means of the inventive method. The shown examples are implants for repair of enchondral and osteochondral defects in joints. However, using the inventive method it is also possible to produce other implants such as e.g. auditory bones or cartilage for plastic surgery e.g. nose cartilage, orbital floors, ear conchs or parts thereof. [0042]
  • FIGS. [0043] 1 to 4 show four exemplified arrangements (in section) for carrying out the inventive method for in vitro production of cartilage tissue;
  • FIGS. [0044] 5 to 7 show chondroitin and collagen contents of different experimental cartilage cultures (of cultures according to the inventive method and of reference cultures according to known methods) in comparison with natural articular cartilage;
  • FIGS. 8 and 9, for illustrating the mechanical properties of cartilage produced according to the inventive method, show forces straining such cartilage (FIG. 8) and straining native cartilage (FIG. 9); [0045]
  • FIGS. [0046] 10 to 13 show light-microscopical and electron-microscopical micrographs of cartilage produced according to the inventive method and of native cartilage.
  • FIG. 14 shows a section through an implant produced according to the inventive method as illustrated in FIG. 2 or [0047] 3, the implant comprising a carrier layer and a cartilage layer (boundary region between the two layers in section perpendicular to the layers);
  • FIGS. 15 and 16 show exemplified embodiments of the inventive implants according to FIG. 14 in section perpendicular to the cartilage layer; [0048]
  • FIGS. [0049] 17 to 20 show examples of applications of implants produced according to the inventive method for the repair of enchondral and osteochondral joint defects (sections perpendicular to the cartilage layer).
  • FIG. 1 shows in section an exemplified arrangement for the inventive in vitro production of cartilage tissue. This arrangement substantially consists of a defined [0050] cell space 1 into which the cells are introduced and which is arranged in a culture medium space 2. At least part of the boundary between the cell space 1 and the culture medium space 2 is formed by a permeable wall, e.g. a semi-permeable membrane 3. The remaining parts of the boundary separating the cell space 1 from the culture medium space 2 are not permeable and consist e.g. of plastic components which give the cell space 1 the predetermined form and hold the semi-permeable membrane in place.
  • In the shown example, an [0051] inner ring 4 and two outer snap- rings 5 and 6 together with two e.g. substantially circular pieces of semi-permeable membrane enclose a cell space 1 in the form of a circular disc.
  • The [0052] semi-permeable membrane 3 has a permeability of 10.000 to 100.000 Dalton. It e.g. consists of the same material as a corresponding dialyse tube. It is obvious that in the same manner as shown in FIG. 1, cell spaces of the most various forms can be created, into which spaces cells are introduced and in which spaces these cells build cartilage tissue, the cartilage tissue substantially assuming the form of the cell space 1 or the form of the one part of cell space 1 which during the culture period faces downward in the direction of gravity.
  • The [0053] culture medium space 2 is a freely selectable space in which the culture medium is periodically exchanged in known manner. If the cell space 1 is to be moved in the culture medium space 2 the culture medium space is e.g. a spinner bottle.
  • Using an arrangement according to FIG. 1, the inventive method is e.g. carried out as follows: [0054]
  • Cells, tissue particles or mixtures of cells and/or tissue particles as described further above are suspended e.g. in culture medium and are introduced into the free cell space such that the cell density is in the range between 5×10[0055] 7 and 109 cells per cm3.
  • The cell space is closed and introduced into the culture medium space and is left there for a period of time in the range of approximately three weeks. [0056]
  • The cartilage tissue formed in the cell space is removed from the cell space and is either cultivated further swimming freely on a culture medium or is directly used as implant or as transplant or for scientific investigations respectively. [0057]
  • In the a cell space according to FIG. 1, implants consisting of cartilage tissue, e.g. auditory bones, nose cartilage, orbital floors or parts thereof are produced. [0058]
  • FIG. 2 shows a further embodiment of a cell space for carrying out the inventive method. The [0059] cell space 1 is flat and its one side is limited by an open pore, rigid or plastically deformable plate 7 made of a possibly biologically degradable bone substitute material, the other side by a permeable wall, e.g. a semi-permeable membrane 3 or a more coarsely porous wall. The cell space has a height of e.g. ca. 3 to 5 mm and any flat form and extension.
  • A cell space as shown in FIG. 2 is especially suited for the production of an implant for repair of a osteochondral defect. The implant comprises not only the cartilage tissue grown in the flat cell space but also the [0060] bone substitute plate 7. This bone substitute plate 7 thus has substantially two functions: during the growth of the cartilage, it serves as permeable wall for the cell space 1 and in the finished implant, it serves as anchoring substrate for the cartilage layer, whereby after implantation this bone substitute material is colonized in known manner by cells immigrating from the adjacent vital bone tissue.
  • In order for the [0061] bone substitute plate 7 to be able to fulfill the second function named above care must be taken that by a corresponding arrangement of the cell space in the culture medium space the cells settle over the whole inner surface of the bone substitute plate 7 at least for a case in which the initial cell density is such that the cells have a settling tendency. Therefore, the cell space 1 is e.g., as shown in FIG. 2, arranged to be stationary with the bone substitute plate 7 facing downward such that the cells settle on the bone substitute plate 7 due to the effect of gravity.
  • Furthermore, the [0062] bone substitute plate 7 must be formed such that the cartilage tissue growing in the cell space 1 is able to grow together with the bone substitute plate 7 in an intermediate region, thus forming a two part implant which can resist shearing forces. This kind of growing together is achieved by choosing the porosity of at least the one surface of the bone substitute plate on which the cartilage is cultivated such that the collagen fibrils built in the extracellular cartilage matrix can grow into the pores and can such anchor the new cartilage in the bone substitute plate. It shows that for this kind of anchoring of the collagen fibers, pores of ca. 1 to 20 μm are suitable.
  • Furthermore, it is advantageous if a part of the cells which are brought onto the surface of the bone substitute plate for cultivating the cartilage settle in uneven places or in pores such that the growing cartilage tissue growth is connected to the bone substitute material in these uneven places and pores in a kind of positive engagement. It shows that cells easily settle in uneven places or pores if these have a size of at least 20 μm, ideally between 20 and 50μ. [0063]
  • Therefore, the [0064] bone substitute plate 7 is to fulfill the following conditions:
  • In order for the cells to be able to be nourished from the culture medium through the bone substitute plate it must comprise pores which form continuous canals (open porosity). [0065]
  • In order for the bone substitute plate to serve at least as a convection barrier against the washing away of larger molecules the pores must not be too large and the thickness of the plate must not be too small. [0066]
  • In order for the collagen fibrils being built in the growing cartilage tissue to be anchored in the pores of the plate the pores must not be larger than 20 μm. [0067]
  • In order for the cells to be able to settle in uneven places or pores in the surface of the bone substitute plate such uneven places or surface pores (surface roughness) having sizes of at least ca. 20 μm must be provided at least on the one part of the surface facing the growing cartilage layer. [0068]
  • It shows that with bone substitute plates having a correspondingly rough surface, having an open porosity with pore sizes in the range of 2 to 20 μm and having a thickness of 0,5 to 3 mm, advantageously 0,5 to 1,5 mm satisfactory results can be achieved. With a plate thickness larger than [0069] ca 0,5 to 1 mm, the region facing away from the bone substitute plate can also have a coarser porosity, e.g. pores with sizes up to 300 to 700 μm such as known from bone substitute materials. This kind of porosity favors the in vivo vascularization of the bone substitute material.
  • As bone substitute material, known osteo-inductive and/or osteo-conductive materials are suitable, advantageously biologically degradable such materials which have the mentioned open porosity and which can be processed to rigid or plastically deformable plates. Plastically deformable plates can e.g. be produced from collagen I, from collagen II and hydroxyapatite or from polylactic acid. Rigid plates can be formed from tricalcium-phosphate, from hydroxyapatite or from other inorganic bone substitute materials. [0070]
  • Treatment of the [0071] bone substitute plate 7 with an attachment factor is unnecessary.
  • In a cell space according to FIG. 2 comprising a correspondingly open-pored [0072] bone substitute plate 7, not only cartilage tissue is grown in vitro but also an implant is produced which comprises a pre-formed, grown together cartilage/bone-intermediate region.
  • FIG. 3 shows a further, exemplified arrangement for carrying out the inventive method. In principle this is a combination of the methods as carried out in arrangements according to FIGS. 1 and 2. The [0073] bone substitute plate 7 is not arranged as part of the permeable wall of the cell space 1 but lies within the cell space which cell space is e.g. limited by semi-permeable membranes 3. It is obvious that in this kind of arrangement the bone substitute plate 7 does not have to take over the function of a convection barrier and that due to this the porosity and thickness of the plate can be chosen at greater liberty.
  • The arrangement shown in FIG. 3 is especially suitable for thin, plastically deformable [0074] bone substitute plates 7 which are complicated to handle as cell space walls.
  • FIG. 4 shows schematically a further embodiment of a [0075] cell space 1 which space is especially suitable for cultivating very thin cartilage layers which are grown together with a bone substitute plate. In opposition to the cell space according to FIGS. 1 to 3, the cell space in FIG. 4 is open towards the top such that at least in the first one to two weeks cultivation must take place under stationary culture conditions. In opposition to similar, known arrangements (e.g. U.S. Pat. No. 5,326,357, Kandel) a bone substitute plate 7 is provided as carrier for the cells and the cells are not applied to the carrier as mono-layer and are not immobilized with the help of an attachment factor.
  • FIGS. [0076] 5 to 7 show results from experiments with the inventive method (experimental arrangement substantially as outlined in FIG. 1). Dialyse tubes were used as semi-permeable membranes.
  • Chondrocytes were isolated from bovine shoulders using known isolation methods. The cells were introduced into the dialyse tubes and these were moved in a spinner bottle during the culture period, whereby the cells settled on the bottommost end of the tubes. HAM-F12 with 5 to 15% serum was used as culture medium. The culture medium was changed every two days. [0077]
  • FIG. 5 shows the contents of chondroitin sulfate and collagen of the cartilage tissue produced according to the inventive method (in μg per ml of cartilage tissue) as a function of the duration of the culture period (20, 29 and 49 days) in comparison with corresponding values of cartilage from bovine shoulders (age: eighteen months). The results show that the content of chondroitin sulfate can be even higher in the cartilage produced in vitro than in natural cartilage, that the content of collagen however is considerably lower. [0078]
  • FIGS. 6 and 7 also show, as a function of the duration of the culture period (0, 7, 20 and 40 days), chondroitin sulfate (FIG. 6) and collagen contents (FIG. 7) in reference cultures A and B and of cartilage tissue grown according to the inventive method after 40 days of culture time (C: cartilage growing in the cell space in the region of the settled cells, D: culture medium in the cell space above the settled cells). For references, chondrocytes were embedded in alginate spheres and cultivated in a stationary culture (reference A) and in a spinner bottle (reference B). [0079]
  • FIGS. 6 and 7 make it clear that the cartilage structure in the experimental arrangement according to the invention is considerably more successful than in the reference experiments. [0080]
  • FIGS. 8 and 9 show results of stress experiments on cartilage produced according to the invention (FIG. 8) and on native cartilage (FIG. 9) in order to illustrate the mechanical properties of the cartilage produced according to the inventive method (for culture conditions see above) compared with the mechanical properties of native bovine cartilage. The experiment consists in pressing a punch into the cartilage with a constant speed (1 micrometer per second) and to stop the punch at a penetration depth of 200 μm while registering the punch force. This force first rises approximately proportionally to the penetration depth and after stopping the punch decreases (visco-elastic force reduction due to loss of liquid of the cartilage tissue). [0081]
  • The two FIGS. 8 and 9 show the punch force in Newton (N) as a function of the time in seconds (s). In FIG. 8 the registering of the depth of penetration (travel) is shown in μm. [0082]
  • The stress experiment with the cartilage produced according to the invention (FIG. 8) was carried out with a punch having a diameter of 20 mm and shows a maximal pressure of ca. 0.8N/cm[0083] 2. The experiment with the native cartilage was carried out with a punch having a diameter of 5 mm and shows a maximal pressure of ca. 30N/cm2.
  • The considerably smaller maximal pressure of the cartilage produced according to the inventive method can be explained in connection with FIGS. [0084] 10 to 13. These Figures show light-microscopical micrographs (FIGS. 10 and 11) and electron-microscopical micrographs (FIGS. 12 and 13) of cartilage produced according to the inventive method (FIGS. 10 and 11) and of human cartilage from the medium zone (FIGS. 12 and 13).
  • FIGS. 10 and 11 clearly show that the cartilage produced according to the inventive method contains considerably more chondrocytes than the native cartilage which can be interpreted as growth stage for the cartilage cultivated in vitro. The same interpretation is suggested by FIGS. 12 and 13 in which organelles are easily visible in the chondrocytes (marked with arrows). In the native cartilage, the organelles are narrow suggesting little synthesis activity; in the cartilage produced according to the invention they are distinctly enlarged which suggests an intense synthesis activity, i.e. a growth stage. [0085]
  • Further electron-microscopical investigations of inventively produced cartilage tissue show that the collagen fibrils form a dense net therein but that they are thinner than in native cartilage (after completed growth) and that they are arranged having random directions. Therefore, the cartilage tissue produced according to the invention must be looked at as a kind of embryonic cartilage tissue which, however has the ability to develop in vivo (after implantation) into ‘grown-up’ cartilage. [0086]
  • FIG. 14 schematically shows a histological section (magnification ca. 100-fold) through the intermediate region between cartilage tissue and bone substitute plate of an implant which was produced in an arrangement according to one of the FIGS. [0087] 2 to 4. The cartilage tissue 10 and the bone substitute plate 7 are connected to each other in an intermediate region in the manner of positive engaging means due to the cartilage tissue having grown into uneven surface places of the bone substitute plate 7.
  • FIGS. 15 and 16 show exemplified embodiments of implants which are produced according to methods as described in connection with FIGS. [0088] 2 to 4 (section through cartilage layer 10). The implants comprise an intermediate region in which the cartilage tissue is grown together with the bone substitute plate 7, as shown in FIG. 14.
  • After a culture period of a few weeks, the [0089] bone substitute plate 7 with the cartilage layer 10 having grown on it is separated from the other wall components of the cell space. Before implantation, the implant consisting of the cartilage layer 10 and the bone substitute plate 7 is reduced to the demanded size and form, if required, and/or is fixed to a further piece 12 of bone substitute material.
  • For processing the implant taken from the cell space, common surgical methods are used, such as e.g. punching, laser cutting or milling. For enlarging the bone substitute plate, a [0090] further piece 12 of a similar or different bone substitute material is attached on the one side of the bone substitute plate 7 opposite to the cartilage layer 10, using a known advantageously biologically degradable cement.
  • After implantation, bone forming cells from the native environment migrate into the open-pore bone substitute material of the [0091] bone substitute plate 7 and of the attached piece 12 and micro-vessels grow into the pores of the material. As a result of this a natural bone tissue develops which gradually replaces the bone substitute material (7, 12, 13) being gradually degraded. Hereby it is to be expected that the cartilage cultivated in vitro is mineralized in the intermediate region 11.
  • FIGS. [0092] 17 to 20 show enchondral and osteochondral defects which are repaired with exemplified embodiments of inventive implants.
  • FIG. 17 shows an enchondral defect with a defined form made by drilling or milling, i.e. a defect which lies in the [0093] native cartilage layer 20 and does not affect the bone tissue 21 underneath the cartilage layer 20. This kind of defect has, in the human case, a depth of maximally ca. 3 mm and can affect any extent of the cartilage surface. A piece of cartilage tissue 10′ is inserted into the prepared defect which cartilage tissue was e.g. cultivated in an arrangement according to FIG. 1 and which cartilage tissue after cultivation was made to fit the form of the defect by cutting or punching, if required.
  • For a satisfactory fixation of the implant in the defect it is sufficient at least for small implants to slightly deform the implant elastically on implantation (press fit). With larger defects the implant is fixed with known means: e.g. with a piece of periosteum which is sutured or glued over the implant, with a glue being introduced between native cartilage and implant (e.g. fibrin glue) or by suturing the implant to the surrounding native cartilage. [0094]
  • FIG. 18 shows a small osteochondral defect which has been prepared for implantation by drilling an opening having a defined form (surface extension up to ca. 10 mm, depth up to ca. 3 mm in the bone tissue), i.e. a defect which does not only affect the [0095] native cartilage tissue 20 but also the bone tissue 21 beneath it. This defect is repaired with an implant according to FIG. 15, which implant is fixed with one or several pins. Two pins are shown. The one pin 22.1 is driven through the implant from its surface by the surgeon, the other pin 22.2 is previously arranged in the bone substitute plate 7 of the implant and is driven into the bone by pressing on the surface of the implant.
  • Obviously, it is also possible to fix the implant in the defect according to FIG. 18 with other fixing means than pins. [0096]
  • From FIG. 18 it can be seen that in the repaired region the considerable shearing forces which act upon the intermediate region between [0097] bone 21 and cartilage 20 when straining the joint are taken over by the intermediate region 11 where the cartilage layer grown in vitro is grown together with the bone substitute plate 7.
  • Instead of an implant consisting of a [0098] cartilage layer 10 cultivated in vitro and a bone substitute plate 7, as shown in FIG. 18, the same defect can also be filled with a filling substance and further repaired with a piece of cartilage tissue cultivated in vitro (without bone substitute plate), in the same way as this is shown in FIG. 17. For taking up the shearing forces in such a case e.g. pins 22.1 reaching right through the implant are to be provided.
  • FIG. 19 shows a prepared osteochondral defect having a depth of 20 to 30 mm and repaired by implantation of an inventive implant according to FIG. 16. Shearing forces are again taken up by the region where the [0099] cartilage layer 10 and the bone substitute plate 7 are grown together. As the cement-connection 13 is positioned within the native bone 21 it is not strained by shearing and thus need not be reinforced by means of a pin.
  • The repair shown in FIG. 18 can also be carried out by filling the lower part of the bore with bone substitute material and by implanting an implant according to FIG. 15, possibly by means of a [0100] cement layer 13.
  • For larger osteochondral defects a plurality of implants according to FIG. 19 can be provided (mosaic plasty). [0101]
  • FIG. 20 shows a large and deep osteochondral defect. It is so large that the cartilage area to be repaired can no longer be approximated with an even area. This kind of defect can, as indicated further above, be repaired with mosaic plasty. However, as the inventive implants are not limited regarding surface size and as the [0102] bone substitute plates 7 can be made of a plastically deformable material, the defect is more easily repaired according to FIG. 20 with an implant according to FIG. 15. For this purpose, the defect is cut out to a depth of a few millimeters into bone 21 and to a defined form, deeper regions are filled with a plastic bone substitute material and the implant is positioned in the defect and fixed with suitable means.

Claims (7)

1. An implant produced by a method for producing an implant comprising cartilage tissue, comprising the steps of:
(a) providing a cell space of a predefined form, said cell space being limited by cell space walls having an inside and an outside surface, wherein said cell space walls are at least in part semi-permeable or have an open porosity suitable as a convection barrier and wherein the inside surface of said cell space walls does not discourage cell attachment;
(b) providing cells with a chondrogenic potential of 5×107 to 109 per cm3 of said cell space;
(c) introducing a mixture consisting of said cells and a suitable culturing medium, or consisting of tissue particles and a suitable culturing medium into said cell space so as to form a culture medium space;
(d) positioning said cell space in culturing medium, such that at least the semi-permeable or porous part of the cell space walls are immersed in said culturing medium;
(e) maintaining a suitable culturing condition for a time period of sufficient duration to allow said cartilage tissue and an implant comprising cartilage tissue to grow in said cell space,
wherein the implant comprises a plate made of an open-pore bone substitute material, the surface of which is at least partly covered with a cartilage layer cultivated in vitro, whereby the cartilage layer is anchored in the bone substitute material by growing into the pores and surface unevenness of the bone substitute material.
2. The implant according to
claim 1
, wherein the plate made of the bone substitute material comprises, at least in the region facing the cartilage layer, pores of a size of 1 to 20 μm and has a thickness of 0.5 to 3 mm.
3. The implant according to
claim 1
, wherein the plate made of bone substitute material is connected to a further part made of bone substitute material by means of a cement layer.
4. The implant according to
claim 1
, wherein the implant is rigid or plastically deformable.
5. A method for repairing enchondral or osteochondral joint defects, comprising the steps of:
producing an implant comprising cartilage tissue according to
claim 1
; and
implanting said implant at a site wherein said enchondral or osteochondral defects are located.
6. A method for producing auditory bones, nose cartilage, orbital floors, ear conchs or parts thereof, comprising the steps of:
producing an implant comprising cartilage tissue according to
claim 1
, wherein said predefined form is in a shape of an auditory bone, nose cartilage, orbital floor, ear conch, or parts thereof.
7. A method for repairing enchondral or osteochondral joint defects, comprising the steps of:
producing an implant comprising cartilage tissue according to
claim 1
; and
implanting said implant at a site wherein said enchondral or osteochondral defects are located, wherein said implant repairs said enchondral or osteochondral joint defects.
US09/836,218 1996-06-04 2001-04-18 Method for producing cartilage tissue and implants for repairing enchondral and osteochondral defects as well as arrangement for carrying out the method Expired - Fee Related US6387693B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/836,218 US6387693B2 (en) 1996-06-04 2001-04-18 Method for producing cartilage tissue and implants for repairing enchondral and osteochondral defects as well as arrangement for carrying out the method

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH140896 1996-06-04
CH1408/96 1996-06-04
US09/194,867 US6242247B1 (en) 1996-06-04 1997-06-02 Method for making cartilage and implants
US09/836,218 US6387693B2 (en) 1996-06-04 2001-04-18 Method for producing cartilage tissue and implants for repairing enchondral and osteochondral defects as well as arrangement for carrying out the method

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/CH1997/000220 Division WO1997046665A1 (en) 1996-06-04 1997-06-02 Method for making cartilage and implants
US09/194,867 Division US6242247B1 (en) 1996-06-04 1997-06-02 Method for making cartilage and implants

Publications (2)

Publication Number Publication Date
US20010014473A1 true US20010014473A1 (en) 2001-08-16
US6387693B2 US6387693B2 (en) 2002-05-14

Family

ID=4209753

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/194,867 Expired - Fee Related US6242247B1 (en) 1996-06-04 1997-06-02 Method for making cartilage and implants
US09/836,218 Expired - Fee Related US6387693B2 (en) 1996-06-04 2001-04-18 Method for producing cartilage tissue and implants for repairing enchondral and osteochondral defects as well as arrangement for carrying out the method

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/194,867 Expired - Fee Related US6242247B1 (en) 1996-06-04 1997-06-02 Method for making cartilage and implants

Country Status (7)

Country Link
US (2) US6242247B1 (en)
EP (1) EP0922093B1 (en)
JP (1) JP3754708B2 (en)
AT (1) ATE250666T1 (en)
DE (1) DE59710789D1 (en)
ES (1) ES2210526T3 (en)
WO (1) WO1997046665A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632247B2 (en) 2000-03-22 2003-10-14 Synthes (Usa) Implants formed of coupled bone
WO2004104183A2 (en) * 2003-05-23 2004-12-02 Haeuselmann Hans Joerg Method for the in vitro production of cartilage-like tissue
US20050125073A1 (en) * 2003-12-08 2005-06-09 Orban Janine M. Implant device for cartilage regeneration in load bearing articulation regions
WO2005058207A1 (en) 2003-12-11 2005-06-30 Isto Technologies, Inc. Particulate cartilage system
EP1619245A1 (en) * 2003-04-15 2006-01-25 Hiroko Yanaga Process for producing cartilage cells for transplantation
US20060034808A1 (en) * 2004-07-30 2006-02-16 The Brigham And Women's Hospital, Inc. Amorphous cell delivery vehicle treated with physical/physicochemical stimuli
US20060111778A1 (en) * 2004-10-29 2006-05-25 Michalow Alexander E Methods of promoting healing of cartilage defects and method of causing stem cells to differentiate by the articular chondrocyte pathway
EP1883398A2 (en) * 2005-02-01 2008-02-06 Osteobiologics, Inc. Method and device for selective addition of a bioactive agent to a multi-phase implant
US20080269895A1 (en) * 2005-09-20 2008-10-30 Steinwachs Matthias R Implant for the Repair of a Cartilage Defect and Method for Manufacturing the Implant
WO2009022191A2 (en) 2007-08-10 2009-02-19 Pécsi Tudományegyetem Articular cartilage, device and method for repairing cartilage defects
EP2039311A1 (en) * 2007-09-20 2009-03-25 DePuy Products, Inc. Orthopaedic Bone Plate and Spacer
US20090209035A1 (en) * 2006-07-10 2009-08-20 Takagi Industrial Co., Ltd. Cell or tissue cultivation apparatus and method of cultivation
US20090298181A1 (en) * 2006-07-10 2009-12-03 Takagi Industrial Co., Ltd. Method of cultivating cell or tissue
US20100279078A1 (en) * 2009-04-30 2010-11-04 Xerox Corporation Structure and method for creating surface texture of compliant coatings on piezo ink jet imaging drums
US8480757B2 (en) 2005-08-26 2013-07-09 Zimmer, Inc. Implants and methods for repair, replacement and treatment of disease
US8497121B2 (en) 2006-12-20 2013-07-30 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US9138318B2 (en) 2007-04-12 2015-09-22 Zimmer, Inc. Apparatus for forming an implant
US9469833B2 (en) 2011-02-04 2016-10-18 Cyfuse Biomedical K. K. Transplantation guide and transplantation device
US10167447B2 (en) 2012-12-21 2019-01-01 Zimmer, Inc. Supports and methods for promoting integration of cartilage tissue explants
WO2022263778A1 (en) * 2021-06-17 2022-12-22 Palingen Implantable device comprising external mobilisation means for the formation of articular cartilage

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE250666T1 (en) * 1996-06-04 2003-10-15 Sulzer Orthopedics Ltd METHOD FOR PRODUCING CARTILAGE TISSUE AND IMPLANTS
US5989269A (en) 1996-08-30 1999-11-23 Vts Holdings L.L.C. Method, instruments and kit for autologous transplantation
US20060025786A1 (en) * 1996-08-30 2006-02-02 Verigen Transplantation Service International (Vtsi) Ag Method for autologous transplantation
US6569172B2 (en) 1996-08-30 2003-05-27 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US20020173806A1 (en) * 1996-08-30 2002-11-21 Verigen Transplantation Service International (Vtsi) Ag Method for autologous transplantation
US8882847B2 (en) 2001-05-25 2014-11-11 Conformis, Inc. Patient selectable knee joint arthroplasty devices
US8480754B2 (en) 2001-05-25 2013-07-09 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US8617242B2 (en) 2001-05-25 2013-12-31 Conformis, Inc. Implant device and method for manufacture
US8556983B2 (en) 2001-05-25 2013-10-15 Conformis, Inc. Patient-adapted and improved orthopedic implants, designs and related tools
US9603711B2 (en) 2001-05-25 2017-03-28 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US8545569B2 (en) 2001-05-25 2013-10-01 Conformis, Inc. Patient selectable knee arthroplasty devices
DE69714035T2 (en) * 1997-08-14 2003-03-06 Sulzer Innotec Ag, Winterthur Composition and device for repairing cartilage tissue in vivo consisting of nanocapsules with osteoinductive and / or chondroinductive factors
US6171610B1 (en) 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
DE19834396C2 (en) * 1998-07-30 2000-07-13 Daimlerchrysler Aerospace Ag Process for the surface coating of medical implants
EP1656960A1 (en) * 1998-08-14 2006-05-17 Verigen AG Methods, instruments and materials for chondrocyte cell transplantation
CN1323228A (en) * 1998-08-14 2001-11-21 维里根国际移植服务(Vtsi)股份公司 Methods instruments and materials for chondrocyte cell transplantation
US7239908B1 (en) 1998-09-14 2007-07-03 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
ATE439806T1 (en) 1998-09-14 2009-09-15 Univ Leland Stanford Junior DETERMINING THE CONDITION OF A JOINT AND PREVENTING DAMAGE
US20030114936A1 (en) * 1998-10-12 2003-06-19 Therics, Inc. Complex three-dimensional composite scaffold resistant to delimination
US6197061B1 (en) * 1999-03-01 2001-03-06 Koichi Masuda In vitro production of transplantable cartilage tissue cohesive cartilage produced thereby, and method for the surgical repair of cartilage damage
DE19911326A1 (en) * 1999-03-15 2000-09-28 Fege Wolfgang Device for growing human or animal tissue
US7476250B1 (en) * 1999-04-06 2009-01-13 Mansmann Kevin A Semi-permeable membranes to assist in cartilage repair
DE19926083A1 (en) * 1999-06-08 2000-12-14 Universitaetsklinikum Freiburg Biological joint construct
US20040115760A1 (en) * 1999-06-18 2004-06-17 Thomas Metzler Method and device for carrying out biochemical reactions with a high throughput
US6179840B1 (en) 1999-07-23 2001-01-30 Ethicon, Inc. Graft fixation device and method
US20020095157A1 (en) 1999-07-23 2002-07-18 Bowman Steven M. Graft fixation device combination
DE19952847B4 (en) * 1999-10-01 2006-03-23 Minuth, Will, Prof. Dr. Device for cultivating and / or differentiating and / or maintaining cells and / or tissues
EP1099443A1 (en) * 1999-11-11 2001-05-16 Sulzer Orthopedics Ltd. Transplant/implant device and method for its production
DE19957388A1 (en) * 1999-11-24 2001-06-13 Michael Sittinger Chondroinductive and implantable substrates for cartilage healing and protection
EP1719463B1 (en) * 1999-12-03 2009-02-25 University Of Leeds Repair of damaged tissue
EP1237511B1 (en) * 1999-12-15 2004-09-01 Sulzer Orthopedics Ltd. Preparation for repairing cartilage defects or cartilage/bone defects in human or animal joints
US6626945B2 (en) * 2000-03-14 2003-09-30 Chondrosite, Llc Cartilage repair plug
US6812048B1 (en) * 2000-07-31 2004-11-02 Eaglestone Partners I, Llc Method for manufacturing a wafer-interposer assembly
US6638312B2 (en) * 2000-08-04 2003-10-28 Depuy Orthopaedics, Inc. Reinforced small intestinal submucosa (SIS)
US8366787B2 (en) 2000-08-04 2013-02-05 Depuy Products, Inc. Hybrid biologic-synthetic bioabsorbable scaffolds
DE60136474D1 (en) 2000-09-14 2008-12-18 Univ R ASSESSMENT OF THE CONDITION OF A JOINT AND LOSS OF CARTEL TISSUE
US20020045260A1 (en) * 2000-10-17 2002-04-18 Shih-Chieh Hung Method of isolating mesenchymal stem cells
CA2365376C (en) 2000-12-21 2006-03-28 Ethicon, Inc. Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
FR2821853B1 (en) * 2001-03-09 2003-05-16 Natural Implant Sa BIOREACTOR FOR THIN FILM CULTIVE TISSUE AND USES
CA2442855A1 (en) * 2001-04-12 2002-10-24 Therics, Inc. Method and apparatus for engineered regenerative biostructures
CA2447694A1 (en) 2001-05-25 2002-12-05 Imaging Therapeutics, Inc. Methods and compositions for articular resurfacing
JP4302515B2 (en) * 2001-07-16 2009-07-29 デピュイ・プロダクツ・インコーポレイテッド Stand-alone surgical apparatus and method
EP1416888A4 (en) 2001-07-16 2007-04-25 Depuy Products Inc Meniscus regeneration device and method
JP4197158B2 (en) * 2001-07-16 2008-12-17 デピュイ・プロダクツ・インコーポレイテッド Devices with naturally occurring biologically derived materials
US8012205B2 (en) 2001-07-16 2011-09-06 Depuy Products, Inc. Cartilage repair and regeneration device
US7819918B2 (en) * 2001-07-16 2010-10-26 Depuy Products, Inc. Implantable tissue repair device
AU2002316694B2 (en) * 2001-07-16 2007-09-06 Depuy Products, Inc. Hybrid biologic/synthetic porous extracellular matrix scaffolds
US7201917B2 (en) * 2001-07-16 2007-04-10 Depuy Products, Inc. Porous delivery scaffold and method
ATE499908T1 (en) * 2001-07-16 2011-03-15 Depuy Products Inc DEVICE FOR REPAIRING CARTILAGE MATERIAL
US8025896B2 (en) * 2001-07-16 2011-09-27 Depuy Products, Inc. Porous extracellular matrix scaffold and method
AU2002335747B2 (en) 2001-09-15 2009-01-29 Rush University Medical Center Stratified cartilage tissue and methods to engineer same
US20030165473A1 (en) * 2001-11-09 2003-09-04 Rush-Presbyterian-St. Luke's Medical Center Engineered intervertebral disc tissue
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US20040166169A1 (en) * 2002-07-15 2004-08-26 Prasanna Malaviya Porous extracellular matrix scaffold and method
US20040136968A1 (en) * 2002-09-27 2004-07-15 Verigen Ag Autologous cells on a support matrix for tissue repair
US7824701B2 (en) 2002-10-18 2010-11-02 Ethicon, Inc. Biocompatible scaffold for ligament or tendon repair
US20040078090A1 (en) 2002-10-18 2004-04-22 Francois Binette Biocompatible scaffolds with tissue fragments
CA2505371A1 (en) 2002-11-07 2004-05-27 Conformis, Inc. Methods for determining meniscal size and shape and for devising treatment
CN100349621C (en) * 2002-12-18 2007-11-21 上海第二医科大学附属第九人民医院 Method for inducing bone marrow substrate stem cell into cartilage
WO2004076608A2 (en) * 2003-02-26 2004-09-10 Georgia Tech Research Corporation Bioreactor and methods for tissue growth and conditioning
AU2004216551B2 (en) 2003-02-26 2008-09-18 Zimmer Orthobiologics, Inc. Preparation for repairing cartilage tissue, especially articular cartilage defects
US8197837B2 (en) 2003-03-07 2012-06-12 Depuy Mitek, Inc. Method of preparation of bioabsorbable porous reinforced tissue implants and implants thereof
US7794408B2 (en) * 2003-03-28 2010-09-14 Ethicon, Inc. Tissue collection device and methods
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
DE10326746B4 (en) * 2003-06-13 2006-04-06 Gerlach, Jörg, Dr.med. Bioreactor in the form of organ copy, process for its preparation and its use for the cultivation, differentiation, preservation and / or use of cells
US8226715B2 (en) 2003-06-30 2012-07-24 Depuy Mitek, Inc. Scaffold for connective tissue repair
US20050013870A1 (en) * 2003-07-17 2005-01-20 Toby Freyman Decellularized extracellular matrix of conditioned body tissues and uses thereof
US10583220B2 (en) * 2003-08-11 2020-03-10 DePuy Synthes Products, Inc. Method and apparatus for resurfacing an articular surface
DE10339953B3 (en) * 2003-08-27 2005-04-21 Coripharm Medizinprodukte Gmbh & Co. Kg. Implant material for bone-cartilage replacement and its use
US7927599B2 (en) * 2003-09-08 2011-04-19 Ethicon, Inc. Chondrocyte therapeutic delivery system
US8257963B2 (en) 2007-06-01 2012-09-04 Depuy Mitek, Inc. Chondrocyte container and method of use
US7897384B2 (en) * 2003-09-08 2011-03-01 Ethicon, Inc. Chondrocyte therapeutic delivery system
US7611473B2 (en) * 2003-09-11 2009-11-03 Ethicon, Inc. Tissue extraction and maceration device
US8034003B2 (en) 2003-09-11 2011-10-11 Depuy Mitek, Inc. Tissue extraction and collection device
US20050085922A1 (en) * 2003-10-17 2005-04-21 Shappley Ben R. Shaped filler for implantation into a bone void and methods of manufacture and use thereof
US7316822B2 (en) 2003-11-26 2008-01-08 Ethicon, Inc. Conformable tissue repair implant capable of injection delivery
US7901461B2 (en) 2003-12-05 2011-03-08 Ethicon, Inc. Viable tissue repair implants and methods of use
US11395865B2 (en) 2004-02-09 2022-07-26 DePuy Synthes Products, Inc. Scaffolds with viable tissue
US8221780B2 (en) 2004-04-20 2012-07-17 Depuy Mitek, Inc. Nonwoven tissue scaffold
US8137686B2 (en) 2004-04-20 2012-03-20 Depuy Mitek, Inc. Nonwoven tissue scaffold
US7569233B2 (en) * 2004-05-04 2009-08-04 Depuy Products, Inc. Hybrid biologic-synthetic bioabsorbable scaffolds
DE102004044102B4 (en) * 2004-09-07 2014-07-31 Technische Universität Dresden Implant for the treatment of osteochondral defects, and process for its preparation
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US7513866B2 (en) * 2004-10-29 2009-04-07 Depuy Products, Inc. Intestine processing device and associated method
CN100384390C (en) * 2005-01-13 2008-04-30 中国人民解放军第三军医大学第一附属医院 Complex tissue of tissue-engineered bone and cartilage and external constructing method thereof
US7815926B2 (en) 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
CA2623106C (en) 2005-09-19 2013-12-24 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
PL1948258T3 (en) * 2005-10-24 2013-05-31 Ed Geistlich Soehne Ag Fuer Chemische Ind Method and device for synovial cell-charged collagen membrane or gel
US7371260B2 (en) * 2005-10-26 2008-05-13 Biomet Sports Medicine, Inc. Method and instrumentation for the preparation and transplantation of osteochondral allografts
US20070178137A1 (en) * 2006-02-01 2007-08-02 Toby Freyman Local control of inflammation
US20070276506A1 (en) * 2006-05-25 2007-11-29 Biomet Manufacturing Corp. Demineralized osteochondral plug
GB0623065D0 (en) * 2006-11-18 2006-12-27 Smith & Nephew Annular ring
US7871440B2 (en) 2006-12-11 2011-01-18 Depuy Products, Inc. Unitary surgical device and method
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
US20090192530A1 (en) * 2008-01-29 2009-07-30 Insightra Medical, Inc. Fortified mesh for tissue repair
US20080294270A1 (en) * 2007-05-24 2008-11-27 Zimmer Orthobiologics, Inc. Differentially processed tissue and processing methods thereof
US20090054906A1 (en) * 2007-08-24 2009-02-26 Zimmer Orthobiologics, Inc. Medical device and method for delivering an implant to an anatomical site
US8303592B2 (en) * 2007-10-05 2012-11-06 Biomet Manufacturing Corp. System for forming a tendon-bone graft
US8322256B2 (en) * 2007-10-05 2012-12-04 Biomet Manufacturing Corp. System for forming a tendon-bone graft
US8852925B2 (en) * 2007-12-17 2014-10-07 The Charlotte-Mecklenburg Hospital Authority Bioreactor for cell growth and associated methods
US8682052B2 (en) 2008-03-05 2014-03-25 Conformis, Inc. Implants for altering wear patterns of articular surfaces
EP2265220A1 (en) 2008-03-05 2010-12-29 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
US8801725B2 (en) * 2008-03-10 2014-08-12 Zimmer Orthobiologics, Inc. Instruments and methods used when repairing a defect on a tissue surface
WO2009140294A1 (en) 2008-05-12 2009-11-19 Conformis, Inc. Devices and methods for treatment of facet and other joints
AU2009268781B2 (en) * 2008-07-06 2015-05-07 The Curators Of The University Of Missouri Osteochondral implants, arthroplasty methods, devices, and systems
US20100166822A1 (en) * 2008-12-31 2010-07-01 Howmedica Osteonics Corp. Adhesive cartilage implant
EP2405865B1 (en) 2009-02-24 2019-04-17 ConforMIS, Inc. Automated systems for manufacturing patient-specific orthopedic implants and instrumentation
WO2011060135A1 (en) 2009-11-12 2011-05-19 Vbi Technologies, Llc Subpopulations of spore-like cells and uses thereof
CA2782137A1 (en) 2009-12-11 2011-06-16 Conformis, Inc. Patient-specific and patient-engineered orthopedic implants
US20130060334A1 (en) * 2010-02-25 2013-03-07 Orteq B.V. Meniscus repair assembly and method
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9113916B2 (en) 2010-08-31 2015-08-25 Zimmer, Inc. Drill bit for osteochondral drilling with guiding element and uses thereof
US8435305B2 (en) 2010-08-31 2013-05-07 Zimmer, Inc. Osteochondral graft delivery device and uses thereof
EP2625577B1 (en) 2010-10-08 2019-06-26 Terumo BCT, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
WO2012112698A2 (en) 2011-02-15 2012-08-23 Conformis, Inc. Patient-adapted and improved articular implants, procedures and tools to address, assess, correct, modify and/or accommodate anatomical variation and/or asymmetry
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
US9017417B2 (en) 2012-05-30 2015-04-28 Kensey Nash Bvf Technology Llc Subchondral bone repair system
KR20150015532A (en) * 2012-05-30 2015-02-10 뉴욕 유니버시티 Tissue repair devices and scaffolds
US9616110B2 (en) 2013-02-28 2017-04-11 Purdue Research Foundation Fabrication method for stratified and layered tissue to repair osteochondral defects
US20140273062A1 (en) * 2013-03-12 2014-09-18 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Cell Pack for the Growth and Manipulation of Three Dimensional Cell Cultures
MX2016001247A (en) 2013-07-30 2016-08-17 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same.
JP6633522B2 (en) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド Cell growth in bioreactors
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
WO2015200266A1 (en) * 2014-06-23 2015-12-30 Community Blood Center Cellular-scale surface modification for increased osteogenic protein expression
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
CN107405422A (en) * 2015-03-18 2017-11-28 富士胶片株式会社 Regenerating bone or cartilage material and its manufacture method
CN107427609A (en) 2015-03-18 2017-12-01 富士胶片株式会社 Regenerating bone or cartilage material
EP3297694A1 (en) 2015-05-21 2018-03-28 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656841A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
US12043823B2 (en) 2021-03-23 2024-07-23 Terumo Bct, Inc. Cell capture and expansion

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308351A (en) * 1980-04-18 1981-12-29 Joseph Leighton System for growing tissue cultures
US4559299A (en) * 1983-02-04 1985-12-17 Brown University Research Foundation Inc. Cytotoxicity assays in cell culturing devices
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
JPS63196281A (en) * 1987-02-12 1988-08-15 Sumitomo Electric Ind Ltd Substrate for cell culture
US5306311A (en) * 1987-07-20 1994-04-26 Regen Corporation Prosthetic articular cartilage
US4904259A (en) * 1988-04-29 1990-02-27 Samuel Itay Compositions and methods for repair of cartilage and bone
US5053050A (en) * 1988-04-29 1991-10-01 Samuel Itay Compositions for repair of cartilage and bone
US5272083A (en) * 1990-10-10 1993-12-21 Costar Corporation Culture device and method of use having a detachable cell or tissue growth surface
US5726060A (en) * 1991-09-17 1998-03-10 Bridges; Michael Anthony Method for culturing mammalian respiratory epithelial cells
US5326357A (en) * 1992-03-18 1994-07-05 Mount Sinai Hospital Corporation Reconstituted cartridge tissue
US5656492A (en) * 1993-02-12 1997-08-12 Brigham And Women's Hospital, Inc. Cell induction device
DE4306661C2 (en) * 1993-03-03 1995-04-20 Michael Dipl Biol Sittinger Process for producing an implant from cell cultures
US5723331A (en) * 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5904716A (en) * 1995-04-26 1999-05-18 Gendler; El Method for reconstituting cartilage tissue using demineralized bone and product thereof
US5759851A (en) * 1995-08-03 1998-06-02 Corning Incorporated Reversible membrane insert for growing tissue cultures
ATE250666T1 (en) * 1996-06-04 2003-10-15 Sulzer Orthopedics Ltd METHOD FOR PRODUCING CARTILAGE TISSUE AND IMPLANTS

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632247B2 (en) 2000-03-22 2003-10-14 Synthes (Usa) Implants formed of coupled bone
US7087087B2 (en) 2000-03-22 2006-08-08 Boyer Ii Michael L Implants formed of coupled bone
AU2004230980B2 (en) * 2003-04-15 2009-07-23 Hiroko Yanaga Process for producing cartilage cells for transplantation
EP1619245A1 (en) * 2003-04-15 2006-01-25 Hiroko Yanaga Process for producing cartilage cells for transplantation
US7704495B2 (en) 2003-04-15 2010-04-27 Hiroko Yanaga Process for producing cartilage cells for transplantation
EP1619245A4 (en) * 2003-04-15 2006-06-21 Hiroko Yanaga Process for producing cartilage cells for transplantation
WO2004104183A2 (en) * 2003-05-23 2004-12-02 Haeuselmann Hans Joerg Method for the in vitro production of cartilage-like tissue
WO2004104183A3 (en) * 2003-05-23 2006-05-18 Hans Joerg Haeuselmann Method for the in vitro production of cartilage-like tissue
US20060127374A1 (en) * 2003-05-23 2006-06-15 Hauselmann Hans J Method for the in vitro production of cartilage-like tissues
US20050125073A1 (en) * 2003-12-08 2005-06-09 Orban Janine M. Implant device for cartilage regeneration in load bearing articulation regions
US7666230B2 (en) 2003-12-08 2010-02-23 Depuy Products, Inc. Implant device for cartilage regeneration in load bearing articulation regions
US8524268B2 (en) 2003-12-11 2013-09-03 Zimmer, Inc. Cadaveric allogenic human juvenile cartilage implant
EP1691727A1 (en) * 2003-12-11 2006-08-23 Isto Technologies Inc. Particulate cartilage system
US8834914B2 (en) 2003-12-11 2014-09-16 Zimmer, Inc. Treatment methods using a particulate cadaveric allogenic juvenile cartilage particles
US8784863B2 (en) 2003-12-11 2014-07-22 Zimmer, Inc. Particulate cadaveric allogenic cartilage system
EP1691727A4 (en) * 2003-12-11 2008-05-07 Isto Technologies Inc Particulate cartilage system
US8765165B2 (en) 2003-12-11 2014-07-01 Zimmer, Inc. Particulate cartilage system
US8652507B2 (en) 2003-12-11 2014-02-18 Zimmer, Inc. Juvenile cartilage composition
WO2005058207A1 (en) 2003-12-11 2005-06-30 Isto Technologies, Inc. Particulate cartilage system
US8518433B2 (en) 2003-12-11 2013-08-27 Zimmer, Inc. Method of treating an osteochondral defect
EP2338442A1 (en) * 2003-12-11 2011-06-29 Isto Technologies Inc. Particulate cartilage system
EP2338441A1 (en) * 2003-12-11 2011-06-29 Isto Technologies Inc. Particulate cartilage system
EP2335650A1 (en) * 2003-12-11 2011-06-22 Isto Technologies Inc. Particulate cartilage system
US20100322994A1 (en) * 2003-12-11 2010-12-23 Isto Technologies, Inc. Particulate cartilage system
EP1781774A4 (en) * 2004-07-30 2009-04-29 Brigham & Womens Hospital Amorphous cell delivery vehicle treated with physical/physicochemical stimuli
AU2005267748B2 (en) * 2004-07-30 2012-09-20 The Brigham And Women's Hospital, Inc. Amorphous cell delivery vehicle treated with physical/physicochemical stimuli
US20090068740A1 (en) * 2004-07-30 2009-03-12 The Brigham And Women's Hospital, Inc. Amorphous cell delivery vehicle treated with physical/physicochemical stimuli
US20060034808A1 (en) * 2004-07-30 2006-02-16 The Brigham And Women's Hospital, Inc. Amorphous cell delivery vehicle treated with physical/physicochemical stimuli
EP1781774A2 (en) * 2004-07-30 2007-05-09 The Brigham And Women's Hospital, Inc. Amorphous cell delivery vehicle treated with physical/physicochemical stimuli
KR101247028B1 (en) 2004-07-30 2013-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. Amorphous Cell Delivery Vehicle Treated with Physical/Physicochemical Stimuli
JP2008507982A (en) * 2004-07-30 2008-03-21 ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド Amorphous cell delivery vehicle processed by physical / physicochemical stimulation
US7462484B2 (en) * 2004-07-30 2008-12-09 The Brigham And Women's Hospital, Inc. Amorphous cell delivery vehicle treated with physical/physicochemical stimuli
US20060111778A1 (en) * 2004-10-29 2006-05-25 Michalow Alexander E Methods of promoting healing of cartilage defects and method of causing stem cells to differentiate by the articular chondrocyte pathway
EP1883398A2 (en) * 2005-02-01 2008-02-06 Osteobiologics, Inc. Method and device for selective addition of a bioactive agent to a multi-phase implant
EP1883398A4 (en) * 2005-02-01 2012-06-06 Osteobiologics Inc Method and device for selective addition of a bioactive agent to a multi-phase implant
US8480757B2 (en) 2005-08-26 2013-07-09 Zimmer, Inc. Implants and methods for repair, replacement and treatment of disease
US8945535B2 (en) 2005-09-20 2015-02-03 Zimmer Orthobiologics, Inc. Implant for the repair of a cartilage defect and method for manufacturing the implant
US20080269895A1 (en) * 2005-09-20 2008-10-30 Steinwachs Matthias R Implant for the Repair of a Cartilage Defect and Method for Manufacturing the Implant
US9005958B2 (en) 2006-07-10 2015-04-14 Purpose Company Limited Cell or tissue cultivation apparatus and method of cultivation
CN105602848A (en) * 2006-07-10 2016-05-25 目的株式会社 Cell or tissue cultivation apparatus and method of cultivation
US8431401B2 (en) 2006-07-10 2013-04-30 Takagi Industrial Co., Ltd. Method of cultivating cell or tissue
US9670450B2 (en) 2006-07-10 2017-06-06 Purpose Company Limited Cell or tissue cultivation apparatus and method of cultivation
US20090209035A1 (en) * 2006-07-10 2009-08-20 Takagi Industrial Co., Ltd. Cell or tissue cultivation apparatus and method of cultivation
US20090298181A1 (en) * 2006-07-10 2009-12-03 Takagi Industrial Co., Ltd. Method of cultivating cell or tissue
US8497121B2 (en) 2006-12-20 2013-07-30 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US9138318B2 (en) 2007-04-12 2015-09-22 Zimmer, Inc. Apparatus for forming an implant
WO2009022191A3 (en) * 2007-08-10 2009-04-16 Pecsi Tudomanyegyetem Articular cartilage, device and method for repairing cartilage defects
WO2009022191A2 (en) 2007-08-10 2009-02-19 Pécsi Tudományegyetem Articular cartilage, device and method for repairing cartilage defects
EP2039311A1 (en) * 2007-09-20 2009-03-25 DePuy Products, Inc. Orthopaedic Bone Plate and Spacer
US20090082816A1 (en) * 2007-09-20 2009-03-26 Graham Matthew R Remodelable orthopaedic spacer and method of using the same
CN101956195B (en) * 2009-04-30 2014-06-04 施乐公司 Structure and method for creating surface texture of compliant coatings on piezo ink jet imaging drums
US8377316B2 (en) * 2009-04-30 2013-02-19 Xerox Corporation Structure and method for creating surface texture of compliant coatings on piezo ink jet imaging drums
CN101956195A (en) * 2009-04-30 2011-01-26 施乐公司 On piezoelectric ink jet imaging drum, generate the structure and the method for the surface texture of submissive coating
US20100279078A1 (en) * 2009-04-30 2010-11-04 Xerox Corporation Structure and method for creating surface texture of compliant coatings on piezo ink jet imaging drums
US9469833B2 (en) 2011-02-04 2016-10-18 Cyfuse Biomedical K. K. Transplantation guide and transplantation device
US10167447B2 (en) 2012-12-21 2019-01-01 Zimmer, Inc. Supports and methods for promoting integration of cartilage tissue explants
WO2022263778A1 (en) * 2021-06-17 2022-12-22 Palingen Implantable device comprising external mobilisation means for the formation of articular cartilage
FR3124067A1 (en) * 2021-06-17 2022-12-23 Palingen Implantable device comprising external mobilization means for the formation of articular cartilage

Also Published As

Publication number Publication date
ES2210526T3 (en) 2004-07-01
WO1997046665A1 (en) 1997-12-11
US6387693B2 (en) 2002-05-14
ATE250666T1 (en) 2003-10-15
EP0922093A1 (en) 1999-06-16
JP3754708B2 (en) 2006-03-15
EP0922093B1 (en) 2003-09-24
DE59710789D1 (en) 2003-10-30
US6242247B1 (en) 2001-06-05
JP2000513214A (en) 2000-10-10

Similar Documents

Publication Publication Date Title
US6387693B2 (en) Method for producing cartilage tissue and implants for repairing enchondral and osteochondral defects as well as arrangement for carrying out the method
US6306169B1 (en) Tissue implant
Sittinger et al. Current strategies for cell delivery in cartilage and bone regeneration
Kreklau et al. Tissue engineering of biphasic joint cartilage transplants
AU2009268781B2 (en) Osteochondral implants, arthroplasty methods, devices, and systems
US7931687B2 (en) Tissue engineered osteochondral implant
US9981063B2 (en) Biosynthetic composite for osteochondral defect repair
JP4406283B2 (en) Tissue regeneration substrate, transplant material, and production method thereof
US20170304058A1 (en) Implant for Repairing a Cartilage Defect
MXPA03002415A (en) Method for treating a patient using a cultured connective tissue construct.
Sebastine et al. Current developments in tissue engineering of nucleus pulposus for the treatment of intervertebral disc degeneration
US11786636B2 (en) Methods for complex tissue engineering
Martin et al. Producing prefabricated tissues and organs via tissue engineering
WO2021086222A1 (en) Method for producing cell spheroids for repairing cartilage
Chong Development of an In Vitro Outer Annulus Fibrosus-Cartilage Endplate Model and its Response to Dynamic Mechanical Loading
CN114787339A (en) Method for producing cohesive cartilage components in vitro
Hwang Compaction of Hydrogels by Compression or Permeation
Maxson The development of a mesenchymal stem cell based biphasic osteochondral tissue engineered construct
Bancroft Bone tissue engineering by cell and matrix transplantation
RUDERT et al. PART V
AU2014277690A1 (en) Scaffolds

Legal Events

Date Code Title Description
AS Assignment

Owner name: CENTERPULSE ORTHOPEDICS LTD., TEXAS

Free format text: CHANGE OF NAME;ASSIGNOR:SULZER ORTHOPEDICS LTD.;REEL/FRAME:015452/0016

Effective date: 19970624

Owner name: ZIMMER GMBH, TEXAS

Free format text: CHANGE OF NAME;ASSIGNOR:CENTERPULSE ORTHOPEDICS LTD.;REEL/FRAME:015452/0023

Effective date: 20040630

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20140514